The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 20, 2018
Filed:
Jun. 30, 2017
Applicant:
Theravance Biopharma R&d Ip, Llc, South San Francisco, CA (US);
Inventors:
Melissa Fleury, Brisbane, CA (US);
Roland Gendron, San Francisco, CA (US);
Adam D. Hughes, Half Moon Bay, CA (US);
Assignee:
THERAVANCE BIOPHARMA R&D IP, LLC, South San Francisco, CA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/675 (2006.01); A61K 31/439 (2006.01); A61K 31/505 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); C07D 239/36 (2006.01); C07D 249/08 (2006.01); C07D 309/32 (2006.01); C07D 401/06 (2006.01); C07D 403/12 (2006.01); A61K 31/351 (2006.01); A61K 31/415 (2006.01); A61K 31/4155 (2006.01); A61K 31/4164 (2006.01); A61K 31/4184 (2006.01); A61K 31/4192 (2006.01); A61K 31/4196 (2006.01); A61K 31/42 (2006.01); A61K 31/437 (2006.01); C07F 9/6518 (2006.01); A61K 31/454 (2006.01); C07D 405/14 (2006.01); C07D 231/20 (2006.01); C07D 233/90 (2006.01); C07D 403/06 (2006.01); C07D 319/06 (2006.01); C07D 471/04 (2006.01); C07D 405/12 (2006.01); C07D 401/04 (2006.01); C07D 309/40 (2006.01); C07D 263/18 (2006.01); C07D 261/12 (2006.01); C07D 249/18 (2006.01); C07D 249/12 (2006.01); C07D 249/10 (2006.01); C07D 249/04 (2006.01); C07D 239/34 (2006.01); C07D 237/14 (2006.01); C07D 235/08 (2006.01); C07D 233/70 (2006.01); C07D 231/18 (2006.01); C07D 231/14 (2006.01); C07C 271/22 (2006.01); C07C 229/34 (2006.01); A61K 31/50 (2006.01); A61K 31/4439 (2006.01); C07D 295/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/675 (2013.01); A61K 31/351 (2013.01); A61K 31/415 (2013.01); A61K 31/4155 (2013.01); A61K 31/4164 (2013.01); A61K 31/4184 (2013.01); A61K 31/4192 (2013.01); A61K 31/4196 (2013.01); A61K 31/42 (2013.01); A61K 31/437 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/50 (2013.01); A61K 31/505 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07C 229/34 (2013.01); C07C 271/22 (2013.01); C07D 231/14 (2013.01); C07D 231/18 (2013.01); C07D 231/20 (2013.01); C07D 233/70 (2013.01); C07D 233/90 (2013.01); C07D 235/08 (2013.01); C07D 237/14 (2013.01); C07D 239/34 (2013.01); C07D 239/36 (2013.01); C07D 249/04 (2013.01); C07D 249/08 (2013.01); C07D 249/10 (2013.01); C07D 249/12 (2013.01); C07D 249/18 (2013.01); C07D 261/12 (2013.01); C07D 263/18 (2013.01); C07D 295/10 (2013.01); C07D 309/32 (2013.01); C07D 309/40 (2013.01); C07D 319/06 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 471/04 (2013.01); C07F 9/65187 (2013.01); C07B 2200/07 (2013.01);
Abstract
In one aspect, the invention relates to compounds having the formula: where R-R, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.